Extended Data Fig. 10. Pairing of 47_E-CAR T and anti-CD47 therapy enhances tumour control in an aggressive osteosarcoma model, even at low doses.

(a – b) hCD8⁺ (left, a) and hCD4⁺ (right, a & b) T cells derived from two independent donors (represented by panels a & b) in the blood on day 14 by flow cytometry after B6H12 treatment in 143B tumour bearing mice, treated with 47_WT- or 47_E-Her2.BBζ-Antares-CAR-T ± B6H12. Mean ± SD of n = 5 mice. (c) hCD4⁺ and hCD8⁺ T cells in the blood on day 14 and day 27 of tumour growth in 143B tumour bearing mice, treated with 47_E-Her2.BBζ-Antares-CAR-T + B6H12. Datapoints represent individual mice, with values from the same mouse connected by lines between time points. (d) T cell BLI prior to B6H12 treatment in mice treated as in (a). Mean ± SD of n = 5 mice. (e) T cell BLI after B6H12 treatment on day 13 in mice treated as in (a). Mean ± SD of n = 5 mice. (f) 47_WT- or 47_E-Her2.BBζ-Antares-CAR-T ± B6H12 treated 143B tumour survival. n = 5 mice/arm. (g and h) 47_WT- or 47_E-Her2.BBζ-Antares-CAR-T ± B6H12 treated 143B tumour (g) growth and (h) survival, using T cells derived from a different donor than (f). Mean ± SEM (g) or representative (h) of n = 5 mice. (i) hCD8⁺ (left) and hCD4⁺ (right) T cells derived from in the blood on day 12 by flow cytometry after treatment with 47_WT- or 47_E-Her2.BBζ-CAR-T ± low-doses of 75 µg or 25 µg B6H12 treatment in 143B tumour bearing mice. Mean ± SD of n = 5 mice. (j) 47_E-Her2.BBζ-CAR-T ± low-dose B6H12 (75 µg or 25 µg) treated 143B tumour growth, using T cells derived from two different donors (left and right panels, respectively). Mice treated with mock T cells were co-treated ± 250 µg (~10 mg/kg) B6H12 (left panel) or 75 µg (~3 mg/kg) B6H12 (right panel). Mean ± SEM of n = 5 mice. [(a), (b), (d), (e), (g), (i), (j)] Two-way ANOVA test with Tukey’s multiple comparison test. ns = not significant. [(f), (h)] Log-rank Mantel-Cox test. ns = not significant.

Source Data